Vaxcyte jumps on phase 3 data for pneumonia vaccine VAX-31
Vaxcyte, Inc., a biotech company based in San Carlos, California, will host a conference call on Monday at 8:00 a.m. ET to share key results from its OPUS-1 adult Phase 3 trial of VAX-31. This vaccine candidate is a 31-valent pneumococcal conjugate vaccine, designed to prevent invasive pneumococcal disease and pneumococcal pneumonia.
The trial evaluated the safety, tolerability, and immunogenicity of VAX-31. Interested parties can join the call by calling 800-445-7795 for those in the United States, or 785-424-1699 for international attendees, using the conference ID PCVX1005. The company is also evaluating VAX-31 in a Phase 2 trial for infants. Vaxcyte is currently developing other pneumococcal vaccine candidates, including a 24-valent version, VAX-24, which demonstrated promising Phase 2 results in adults and infants.
The company's pipeline also includes vaccines for expanded pneumococcal coverage, prevention of Group A Streptococcus, and protection against Shigella. Vaxcyte uses its XpressCF cell-free protein synthesis platform, licensed from Sutro Biopharma, Inc., in its vaccine development efforts.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data biopharmadive.com
- Vaxcyte to present phase 3 trial data for vaccine candidate investing.com